Dare Bioscience (DARE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

DARE Dare Bioscience

Watchlist

3.1801
-0.0099-0.31%

Trading Dec 13 13:27 ET

27.67MMarket Cap-5.48P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Dare Bioscience Announces Publication in Sexual Medicine on RESPOND Study
TipRanksDec 10 08:10 ET
Express News | Daré Bioscience Announces Publication In Sexual Medicine Highlighting Positive Subgroup Findings From Phase 2b RESPOND Study Of Sildenafil Cream, 3.6%, For Female Sexual Arousal Disorder
BenzingaDec 10 08:07 ET
Dare Bioscience Received Payment of $2.5M Under Grant Agreement
TipRanksDec 4 08:12 ET
Press Release: Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Dow JonesDec 4 08:00 ET
Maxim Group Maintains Dare Bioscience(DARE.US) With Hold Rating
Moomoo NewsNov 16 10:32 ET · Ratings
Dare Bioscience Files to Sell 2.75M Shares of Common Stock for Holders
TipRanksNov 15 17:20 ET

Comments

Jaguar8

Dec 4 18:31

NEWS

$Dare Bioscience (DARE.US)$
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience received a $2.5 million grant installment for developing DARE-LARC1, a novel contraceptive technology. This payment is part of a larger $49 million grant agreement, of which $31.8 million has been received to date. DARE-LARC1 represents a potential new category of long-acting, reversible contraceptive featuring...

Trytosaveabit

Nov 13 07:04

News

$Dare Bioscience (DARE.US)$ Reuters
3 mins ago
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites

Jaguar8

Nov 13 07:00

NEWS

$Dare Bioscience (DARE.US)$
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
Daré Bioscience (NASDAQ: DARE) has secured a grant of up to $10.7 million from the Bill & Melinda Gates Foundation. The funding will support two key initiatives: the development of a novel non-hormonal intravaginal contraceptive product candidate and the expansion of clinical sites for the ongoing Ovapr...

Jaguar8

Oct 23 21:59

Put on watch. $10M award. News came after market opened/mid day. Didn’t run. Low float

$Dare Bioscience (DARE.US)$

Trytosaveabit

Oct 23 11:50

New 8K filed in last 15 minutes

$Dare Bioscience (DARE.US)$ Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management.

Essentially all cervical cancer cases worldwide are caused by HPV infection.

SAN DIEGO, October 23, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE),...

Heat List

Overall

No Data